<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02138916</url>
  </required_header>
  <id_info>
    <org_study_id>D3251C00003</org_study_id>
    <nct_id>NCT02138916</nct_id>
  </id_info>
  <brief_title>Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History</brief_title>
  <acronym>GALATHEA</acronym>
  <official_title>Randomised, Double-blind, 56 Week Placebo-controlled, Parallel Group, Multicentre, Phase 3 Study to Evaluate the Efficacy and Safety of 2 Doses of Benralizumab in Patients With Moderate to Very Severe COPD With a History of Exacerbations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine if benralizumab reduces COPD exacerbation rate in
      symptomatic patients with moderate to very severe COPD who are receiving standard of care
      therapies
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 13, 2014</start_date>
  <completion_date type="Actual">April 10, 2018</completion_date>
  <primary_completion_date type="Actual">April 10, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS&gt;=220/uL</measure>
    <time_frame>From first IP to week 56</time_frame>
    <description>A COPD exacerbation is defined by symptomatic worsening of COPD requiring:
Use of systemic corticosteroids for at least 3 days; a single depot injectable dose of corticosteroids will be considered equivalent to a 3-day course of systemic corticosteroids; and/or
Use of antibiotics; and/or
An inpatient hospitalization or death due to COPD Annual COPD exacerbation rate is the number of exacerbations per year. Its raw rate is calculated by number of exacerbations divided by the treatment period and then normalized to an annual rate, and is estimated by negative binomial model. Rate ratio between two treatment groups is also estimated through this model.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS&lt;220/uL</measure>
    <time_frame>From first IP to week 56</time_frame>
    <description>A COPD exacerbation is defined by symptomatic worsening of COPD requiring:
Use of systemic corticosteroids for at least 3 days; a single depot injectable dose of corticosteroids will be considered equivalent to a 3-day course of systemic corticosteroids; and/or
Use of antibiotics; and/or
An inpatient hospitalization or death due to COPD Annual COPD exacerbation rate is the number of exacerbations per year. Its raw rate is calculated by number of exacerbations divided by the treatment period and then normalized to an annual rate, and is estimated by negative binomial model. Rate ratio between two treatment groups is also estimated through this model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline EOS&gt;=220/uL</measure>
    <time_frame>First IP up to end of treatment Week 56</time_frame>
    <description>Pre-bronchodilator FEV1 (L) is collected at Weeks 0, 4, 8, 16, 24, 32, 40, 48, and 56. Baseline is the last non-missing value with quality (acceptable or borderline quality grade) prior to the first dose of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in SGRQ Total Score for Patients With Baseline EOS&gt;=220/uL</measure>
    <time_frame>First IP up to Week 56</time_frame>
    <description>SGRQ is from 50-item PRO instrument. The SGRQ total score is expressed as a percentage of overall impairment, in which 100% means the worst possible health status and 0 indicates the best possible health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in CAT Total Score for Patients With Baseline EOS&gt;=220/uL</measure>
    <time_frame>First IP up to Week 56</time_frame>
    <description>CAT is an 8-item PRO developed to measure the impact of COPD on health status. The instrument uses semantic differential six-point response scales. A CAT total score is the sum of item responses. Score ranges from 0 to 40 with higher scores indicative of greater COPD impact on health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in E-RS: COPD Total Score for Patients With Baseline EOS&gt;=220/uL</measure>
    <time_frame>First IP up to Week 56</time_frame>
    <description>The E-RS: COPD is an 11-item PRO developed to evaluate the severity of respiratory symptoms of COPD. Summation of E-RS: COPD item responses produces a total score ranging from 0 to 40, with higher scores indicating greater severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Total Rescue Medication Use (Number of Puffs Per Day) for Patients With Baseline EOS&gt;=220/uL</measure>
    <time_frame>First IP up to Week 56</time_frame>
    <description>The number of rescue medication inhalations and nebulizer treatments taken are recorded by the patient in the eDiary twice daily. Total rescue medication use is the sum of daytime and night-time use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Proportion of Nights Awakenings Due to Respiratory Symptoms for Patients With Baseline EOS&gt;=220/uL</measure>
    <time_frame>First IP up to Week 56</time_frame>
    <description>Change from baseline to week 56 in proportion of nights awakenings due to respiratory symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants by Number of COPD Exacerbations Based on EXACT-PRO for Patients With Baseline EOS&gt;=220/uL</measure>
    <time_frame>Immediately following first IP up to week 56</time_frame>
    <description>The EXACT-PRO is a 14-item PRO instrument developed to assess the frequency, severity and duration of COPD exacerbations. Respondents are instructed to complete the electronic diary (eDiary) each evening just prior to bedtime and to answer the questions while onsidering their experiences &quot;today&quot;. The daily EXACT-PRO total score has a range of 0-100 with higher scores indicative of greater severity. Exacerbation event frequency is calculated by comparing the baseline with daily total scores. An increase in EXACT-PRO total score ≥9 for 3 days or ≥12 for 2 days indicate an exacerbation event has occurred.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of EXACT-PRO for Patients With Baseline EOS&gt;=220/uL</measure>
    <time_frame>Immediately following first IP up to week 56</time_frame>
    <description>The EXACT-PRO is a 14-item PRO instrument developed to assess the frequency, severity and duration of COPD exacerbations. Respondents are instructed to complete the electronic diary (eDiary) each evening just prior to bedtime and to answer the questions while onsidering their experiences &quot;today&quot;. The daily EXACT-PRO total score has a range of 0-100 with higher scores indicative of greater severity. Severity for the study is the highest score of EXACT-PRO.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of EXACT-PRO for Patients With Baseline EOS&gt;=220/uL</measure>
    <time_frame>Immediately following first IP up to week 56</time_frame>
    <description>The EXACT-PRO is a 14-item PRO instrument developed to assess the frequency, severity and duration of COPD exacerbations. Respondents are instructed to complete the electronic diary (eDiary) each evening just prior to bedtime and to answer the questions while onsidering their experiences &quot;today&quot;. The daily EXACT-PRO total score has a range of 0-100 with higher scores indicative of greater severity. Event frequency is calculated by comparing the baseline with daily total scores. An increase in EXACT-PRO total score ≥9 for 3 days or ≥12 for 2 days indicate an event has occurred. Calculation of event duration after identification of the following five parameters: 1) onset; 2) three-day rolling average; 3) maximum observed value; 4) threshold for improvement; and 5) recovery. That is, duration of the exacerbation is the time elapse between onset and recovery of the event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual EXACT-PRO Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS&gt;=220/uL</measure>
    <time_frame>Immediately following first IP up to week 56</time_frame>
    <description>The EXACT-PRO is a 14-item PRO instrument developed to assess the frequency, severity and duration of COPD exacerbations. Respondents are instructed to complete the electronic diary (eDiary) each evening just prior to bedtime and to answer the questions while onsidering their experiences &quot;today&quot;. The daily EXACT-PRO total score has a range of 0-100 with higher scores indicative of greater severity. Event frequency is calculated by comparing the baseline with daily total scores. An increase in EXACT-PRO total score ≥9 for 3 days or ≥12 for 2 days indicate an event has occurred. Annual EXACT-PRO exacerbation rate is the number of exacerbations per year. Its raw rate is calculated by number of exacerbations divided by the treatment period and then normalized to an annual rate, and is estimated by negative binomial model. Rate ratio between two treatment groups is also estimated through this model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Having at Least 1 COPD Exacerbation for Patients With Baseline EOS&gt;=220/uL</measure>
    <time_frame>Immediately following first IP up to week 56</time_frame>
    <description>A COPD exacerbation is defined by symptomatic worsening COPD requiring systemic corticosteroids, antibiotics, or an inpatient hospitalization/death due to COPD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First COPD Exacerbation</measure>
    <time_frame>Immediately following first IP up to week 56</time_frame>
    <description>Time to first COPD exacerbation is from the randomization date to the first occurrence of COPD exacerbation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual COPD Exacerbation Rate Associated With ER or Hospitalization Over 56 Weeks Treatment Comparison for Patients With Baseline EOS&gt;=220/uL</measure>
    <time_frame>Immediately following first IP up to week 56</time_frame>
    <description>Annual COPD exacerbations rate that result in ER or hospitalization is calculated by number of exacerbations resulting ER or hospitalization divided by the treatment period and then normalized to an annual rate, and is estimated by negative binomial model. Rate ratio between two treatment groups is also estimated through this model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Had COPD-related Healthcare Encounter for Patient With Baseline EOS&gt;=220/uL</measure>
    <time_frame>Immediately following first IP up to week 56</time_frame>
    <description>Types of healthcare encounter: Hospitalisations (inc. intensive care and/or general care), Emergency department visits, Unscheduled outpatients visits, Home visits, Telephone calls, and ambulance transports.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Study Treatment Administration</measure>
    <time_frame>From first dose date to last dose date, 48 weeks per protocol.</time_frame>
    <description>Duration of study treatment is calculated from first dose date to last dose date + 1 day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of Benralizumab</measure>
    <time_frame>Pre-first dose and pre-dose at end of treatment (week 56)</time_frame>
    <description>PK serum samples were collected pre-dose at each visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of Benralizumab</measure>
    <time_frame>Pre-treatment until end of follow-up, week 60 per protocol.</time_frame>
    <description>Antidrug antibody (ADA) responses such as ADA prevalence, ADA incidence, ADA persistently positive counts, etc. were presented</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1656</enrollment>
  <condition>Moderate to Very Severe Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Benralizumab Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Benralizumab administered subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Benralizumab Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Benralizumab administered subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered subcutaneously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benralizumab Arm A</intervention_name>
    <description>Benralizumab subcutaneously on study week 0 until study week 48 inclusive</description>
    <arm_group_label>Benralizumab Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benralizumab Arm B</intervention_name>
    <description>Benralizumab subcutaneously on study week 0 until study week 48 inclusive</description>
    <arm_group_label>Benralizumab Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo subcutaneously on study week 0 until study week 48 inclusive</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:1.Informed consent. 2.Subjects 40-85 y.o. 3.Moderate to very severe COPD
        with Post Bronchodilator (BD) FEV1&gt;20% and ≤65%. 4.≥2 moderate or ≥1 severe COPD
        exacerbation(s) required treatment or hospitalization within 2-52 weeks prior to Visit1. 5.
        Modified Medical Research Council (mMRC) score ≥1 at Visit 1. 6.Treatment with double or
        triple therapy throughout the year prior to Visit 1, constant 2 weeks prior to Visit 1.
        7.Tobacco history of ≥10 pack-years. 8.Women of childbearing potential must use a highly
        effective form of birth control from Visit 1 until 16 weeks after their last dose, and
        negative serum pregnancy test result at Visit 1. 9.Male subjects who are sexually active
        must be surgically sterile one year prior to Visit 1 or use an adequate method of
        contraception from the first Investigational Product (IP) dose until 16 weeks after their
        last dose. 10.Compliance with maintenance therapy during run-in ≥70%. 11. Blood eosinophils
        due to subject's stratification and cap for blood eosinophil levels.When any eosinophil
        cohort is full, subjects in the completed cohort will not be randomised and will be
        withdrawn from the study. Exclusion criteria: 1. Clinically important pulmonary disease
        other than COPD or another diagnosed pulmonary or systemic disease associated with elevated
        peripheral eosinophil counts.

        2. Any disorder or major physical impairment that is not stable by Investigator opinion
        and/or could affect: - subject safety−study findings or their interpretation or subject's
        ability to complete the entire study duration.

        3. Unstable ischemic heart disease, arrhythmia, cardiomyopathy, or other relevant
        cardiovascular disorder that in Investigator's judgment may put the patient at risk or
        negatively affect the study outcome.

        4. Treatment with systemic corticosteroids and/or antibiotics, and/or hospitalization for a
        COPD exacerbation within 2 weeks prior to Visit1 or during the enrolment and run-in period.

        5. Acute upper or lower respiratory infection requiring antibiotics or antiviral medication
        within 2 weeks prior to Visit1or during the enrolment and run-in period.

        6. Pneumonia within 8 weeks prior to Visit1 or during the enrolment and run-in period.

        7. Pregnant, breastfeeding, or lactating women. 8. Risk factors for pneumonia 9. History of
        anaphylaxis to any other biologic therapy. 10. Long term oxygen therapy with signs and/or
        symptoms of cor pulmonale, right ventricular failure.

        11. Use of immunosuppressive medication within 2 weeks prior to Visit1 and/or during the
        enrolment and run-in period.

        12. Receipt of any investigational non-biologic product within 30 days or 5 half-lives
        prior to Visit 1.

        13. Evidence of active tuberculosis (TB) without an appropriate course of treatment.

        14. Lung volume reduction surgery within the 6 months prior to Visit 1. History of partial
        or total lung resection (single lobe or segmentectomy is acceptable).

        15. Asthma as a primary or main diagnosis according to the Global Initiative for Asthma
        (GINA) guidelines or other accepted guidelines.

        16. Previous treatment with benralizumab. 17. Helminth parasitic infection diagnosed within
        24 weeks prior to Visit 1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerard Criner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Temple University School of Medicine, 3401 North Broad Street, Suite 745 PP, Philadelphia, PA 19140</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Andalusia</city>
        <state>Alabama</state>
        <zip>36420</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jasper</city>
        <state>Alabama</state>
        <zip>35501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gold River</city>
        <state>California</state>
        <zip>95670</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Huntington Park</city>
        <state>California</state>
        <zip>90255-6046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lakewood</city>
        <state>California</state>
        <zip>90805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lomita</city>
        <state>California</state>
        <zip>90717</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Palm Desert</city>
        <state>California</state>
        <zip>92260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Thousand Oaks</city>
        <state>California</state>
        <zip>91360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520-8057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Loxahatchee Groves</city>
        <state>Florida</state>
        <zip>33470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami Springs</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Panama City</city>
        <state>Florida</state>
        <zip>32405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32129</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sebring</city>
        <state>Florida</state>
        <zip>33870</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <zip>32960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789-4681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Calhoun</city>
        <state>Georgia</state>
        <zip>30701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Duluth</city>
        <state>Georgia</state>
        <zip>30096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Eagle</city>
        <state>Idaho</state>
        <zip>83616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aurora</city>
        <state>Illinois</state>
        <zip>60506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Michigan City</city>
        <state>Indiana</state>
        <zip>46360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valparaiso</city>
        <state>Indiana</state>
        <zip>46383</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fort Mitchell</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hazard</city>
        <state>Kentucky</state>
        <zip>41701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <zip>21044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <zip>02747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48336</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rochester</city>
        <state>Michigan</state>
        <zip>48307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Charles</city>
        <state>Missouri</state>
        <zip>63301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <zip>07901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bronxville</city>
        <state>New York</state>
        <zip>10708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fayetteville</city>
        <state>New York</state>
        <zip>13066</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Elizabeth City</city>
        <state>North Carolina</state>
        <zip>27909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gastonia</city>
        <state>North Carolina</state>
        <zip>28054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mount Airy</city>
        <state>North Carolina</state>
        <zip>27030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Bern</city>
        <state>North Carolina</state>
        <zip>28562</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45459</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bend</city>
        <state>Oregon</state>
        <zip>97701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <zip>16602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jefferson Hills</city>
        <state>Pennsylvania</state>
        <zip>15025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gaffney</city>
        <state>South Carolina</state>
        <zip>29340</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Indian Land</city>
        <state>South Carolina</state>
        <zip>29707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rock Hill</city>
        <state>South Carolina</state>
        <zip>29732</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <zip>37067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hendersonville</city>
        <state>Tennessee</state>
        <zip>37075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boerne</city>
        <state>Texas</state>
        <zip>78006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frisco</city>
        <state>Texas</state>
        <zip>75034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77077</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Midvale</city>
        <state>Utah</state>
        <zip>84047</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Provo</city>
        <state>Utah</state>
        <zip>84604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Richland</city>
        <state>Washington</state>
        <zip>99352</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Feldkirch</city>
        <zip>6800</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wels</city>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wien</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2Y 2Z7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sherwood Park</city>
        <state>Alberta</state>
        <zip>T8L 0N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ajax</city>
        <state>Ontario</state>
        <zip>L1Z 0M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <zip>L7N 3V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Grimsby</city>
        <state>Ontario</state>
        <zip>L3M 1P3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pointe-Claire</city>
        <state>Quebec</state>
        <zip>H9R 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1V 4W2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St Charles Borromee</city>
        <state>Quebec</state>
        <zip>J6E 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Trois Rivieres</city>
        <state>Quebec</state>
        <zip>G8T 7A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1G 3Y8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jindrichuv Hradec</city>
        <zip>377 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Karlovy Vary</city>
        <zip>360 17</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kralupy nad Vltavou</city>
        <zip>278 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mlada Boleslav</city>
        <zip>293 50</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Olomouc</city>
        <zip>775 21</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 8</city>
        <zip>182 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rokycany</city>
        <zip>337 22</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Strakonice</city>
        <zip>386 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Teplice</city>
        <zip>415 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bamberg</city>
        <zip>96049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>10787</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>13187</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bonn</city>
        <zip>53123</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frankfurt/Main</city>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Geesthacht</city>
        <zip>21502</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20354</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04357</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Neu-Isenburg</city>
        <zip>63263</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rodgau-Dudenhofen</city>
        <zip>63110</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Teuchern</city>
        <zip>06682</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Witten</city>
        <zip>58452</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Balassagyarmat</city>
        <zip>2660</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>1135</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>1204</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edelény</city>
        <zip>3780</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Farkasgyepü</city>
        <zip>8582</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gödöllő</city>
        <zip>2100</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hajdúnánás</city>
        <zip>4080</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hatvan</city>
        <zip>3000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miskolc</city>
        <zip>3529</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mátraháza</city>
        <zip>3233</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pécs</city>
        <zip>7626</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pécs</city>
        <zip>7635</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szeged</city>
        <zip>H-6722</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Százhalombatta</city>
        <zip>2440</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Székesfehérvár</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bolzano</city>
        <zip>39100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Catania</city>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ferrara</city>
        <zip>44100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orbassano</city>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Palermo</city>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Parma</city>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tradate</city>
        <zip>21049</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chuo-ku</city>
        <zip>103-0027</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukuoka-shi</city>
        <zip>811-1394</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukuoka-shi</city>
        <zip>819-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukuyama-shi</city>
        <zip>720-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Higashiibaraki-gun</city>
        <zip>311-3193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Himeji-shi</city>
        <zip>670-0849</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Himeji-shi</city>
        <zip>672-8064</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hirosaki-shi</city>
        <zip>036-8545</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iwata-shi</city>
        <zip>438-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Izumo-shi</city>
        <zip>693-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Joyo-shi</city>
        <zip>610-0113</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kagoshima-shi</city>
        <zip>890-0064</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kasuga-shi</city>
        <zip>816-0813</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kasugai-shi</city>
        <zip>486-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kawaguchi-shi</city>
        <zip>333-0833</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kawasaki-shi</city>
        <zip>211-0041</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kiryu-shi</city>
        <zip>376-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kishiwada-shi</city>
        <zip>596-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kitakami-shi</city>
        <zip>024-8506</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kobe-shi</city>
        <zip>650-0047</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kochi-shi</city>
        <zip>780-8077</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kodaira-shi</city>
        <zip>187-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kokubunji-shi</city>
        <zip>185-0014</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koshi-shi</city>
        <zip>861-1196</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kuki-shi</city>
        <zip>349-1105</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kumamoto-shi</city>
        <zip>862-0921</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kurashiki-shi</city>
        <zip>711-0921</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kurume-shi</city>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyoto-shi</city>
        <zip>615-8256</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Matsue-shi</city>
        <zip>690-8506</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Matsue-shi</city>
        <zip>690-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Matsumoto-shi</city>
        <zip>390-0872</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Matsusaka-shi</city>
        <zip>515-8544</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Meguro-ku</city>
        <zip>153-8515</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mizunami-shi</city>
        <zip>509-6134</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Morioka-shi</city>
        <zip>020-0055</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagaoka-shi</city>
        <zip>940-8621</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagoya-shi</city>
        <zip>454-8509</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagoya-shi</city>
        <zip>455-8530</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Niigata-shi</city>
        <zip>950-2085</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Obihiro-shi</city>
        <zip>080-0805</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ohota-ku</city>
        <zip>145-0063</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ota-shi</city>
        <zip>373-8585</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saiki-shi</city>
        <zip>876-0813</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sakai-shi</city>
        <zip>591-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sakaide-shi</city>
        <zip>762-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sapporo-shi</city>
        <zip>001-0901</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sapporo-shi</city>
        <zip>060-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sapporo-shi</city>
        <zip>063-0005</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sapporo-shi</city>
        <zip>064-0804</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sendai-shi</city>
        <zip>984-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seto-shi</city>
        <zip>489-8642</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shinagawa-ku</city>
        <zip>142-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shinjuku-ku</city>
        <zip>162-8655</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Takamatsu-shi</city>
        <zip>761-8073</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Takatsuki-shi</city>
        <zip>569-1096</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toon-shi</city>
        <zip>791-0281</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toshima-ku</city>
        <zip>171-0014</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ube-shi</city>
        <zip>755-0241</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ueda-shi</city>
        <zip>386-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uji-shi</city>
        <zip>611-0041</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Urasoe-shi</city>
        <zip>901-2132</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uruma-shi</city>
        <zip>904-2293</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yachiyo-shi</city>
        <zip>276-8524</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yanagawa-shi</city>
        <zip>832-0059</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yao-shi</city>
        <zip>581-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yokohama-shi</city>
        <zip>232-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yokohama-shi</city>
        <zip>234-0054</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yokohama-shi</city>
        <zip>236-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yokohama-shi</city>
        <zip>236-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucheon-si</city>
        <zip>14584</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Daegu</city>
        <zip>42415</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>03312</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>04401</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>05030</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wonju-si</city>
        <zip>26426</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Breda</city>
        <zip>4818 CK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heerlen</city>
        <zip>6419 PC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Horn</city>
        <zip>6085 NM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zwolle</city>
        <zip>8025 AB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-681</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dobre Miasto</city>
        <zip>11-040</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-405</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gdańsk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Katowice</city>
        <zip>40-081</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kościan</city>
        <zip>64-000</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kraków</city>
        <zip>31-011</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kraków</city>
        <zip>31-209</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-064</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-089</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-468</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mrozy</city>
        <zip>05-320</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mrągowo</city>
        <zip>11-700</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-357</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Proszowice</city>
        <zip>32-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Radom</city>
        <zip>26-617</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ruda Slaska</city>
        <zip>41-709</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rzeszów</city>
        <zip>35-241</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tarnów</city>
        <zip>33-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>53-201</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wrocław</city>
        <zip>50-220</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zakopane</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Łódź</city>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bragadiru</city>
        <zip>077025</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brasov</city>
        <zip>500283</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucharest</city>
        <zip>030303</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucharest</city>
        <zip>71593</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Constanta</city>
        <zip>900002</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Deva</city>
        <zip>330061</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iasi</city>
        <zip>700115</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Timisoara</city>
        <zip>300310</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620039</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620109</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620137</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620219</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ivanovo</city>
        <zip>153005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Izhevsk</city>
        <zip>426035</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kazan</city>
        <zip>420012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kemerovo</city>
        <zip>650000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kemerovo</city>
        <zip>650002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kemerovo</city>
        <zip>650066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>109240</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>117593</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>121309</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>127018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>127473</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603126</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630008</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630051</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630084</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Penza</city>
        <zip>440067</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Perm</city>
        <zip>614068</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pskov</city>
        <zip>180007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pyatigorsk</city>
        <zip>357500</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ryazan</city>
        <zip>390026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>193312</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197342</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>196084</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saratov</city>
        <zip>410012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Smolensk</city>
        <zip>214019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>196247</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197089</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St.Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tomsk</city>
        <zip>634050</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tomsk</city>
        <zip>634063</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ufa</city>
        <zip>450071</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ulyanovsk</city>
        <zip>432009</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vladikavkaz</city>
        <zip>362007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vladimir</city>
        <zip>600023</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Volgograd</city>
        <zip>400001</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Volgograd</city>
        <zip>400131</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amanzimtoti</city>
        <zip>4126</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cape Town</city>
        <zip>7764</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durban</city>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gauteng</city>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Middelburg</city>
        <zip>1055</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Alicante</city>
        <zip>03004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Badalona(Barcelona)</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>07010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sabadell (Barcelona)</city>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Biel</city>
        <zip>2502</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gossau</city>
        <zip>CH-9202</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Liestal</city>
        <zip>CH-4410</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aberdeen</city>
        <zip>AB25 2ZG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bradford</city>
        <zip>BD9 6RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chertsey</city>
        <zip>KT16 0PZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4TJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Le3 9qp</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <zip>SE5 9PJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manchester</city>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newcastle-Under-Lyme</city>
        <zip>ST4 6QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newcastle-Upon-Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Southampton</city>
        <zip>SO166YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wishaw</city>
        <zip>ML2 0DP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wolverhampton</city>
        <zip>WV10 0QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=2562&amp;filename=Galathea_CSP_and_last_amendment_Redacted.pdf</url>
    <description>Clinical Study protocol</description>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=2562&amp;filename=D3251C00003_Statistical_Analysis_Plan_Redacted.pdf</url>
    <description>Statistical Analysis Plan (SAP)</description>
  </link>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>March 26, 2014</study_first_submitted>
  <study_first_submitted_qc>May 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2014</study_first_posted>
  <results_first_submitted>March 19, 2019</results_first_submitted>
  <results_first_submitted_qc>June 12, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 13, 2019</results_first_posted>
  <last_update_submitted>June 12, 2019</last_update_submitted>
  <last_update_submitted_qc>June 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obstructive Lung Diseases</keyword>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <keyword>Lung Disease</keyword>
  <keyword>Bronchial Diseases</keyword>
  <keyword>COPD Exacerbation</keyword>
  <keyword>Respiratory Tract Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benralizumab</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 23, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/16/NCT02138916/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 6, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/16/NCT02138916/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>1656 patients randomized to Benralizumab 30 mg, Benralizumab 100 mg, or Placebo. All randomized patients were treated. 554 (33.5%) were randomized to Benralizumab 30 mg, 552 (33.3%) were randomized to Benralizumab 100 mg, and 550 (33.2%) were randomized to Placebo.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Benralizumab 30 mg</title>
          <description>Every 8 weeks administered subcutaneously</description>
        </group>
        <group group_id="P2">
          <title>Benralizumab 100 mg</title>
          <description>Every 8 weeks administered subcutaneously</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Every 8 weeks administered subcutaneously</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="554"/>
                <participants group_id="P2" count="552"/>
                <participants group_id="P3" count="550"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="497"/>
                <participants group_id="P2" count="492"/>
                <participants group_id="P3" count="491"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="60"/>
                <participants group_id="P3" count="59"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>eg., meds change, lack of efficacy, etc.</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="32"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study specific withdrawal criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>incorrect enrolment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Severe non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Benralizumab 30 mg</title>
          <description>Every 8 weeks administered subcutaneously</description>
        </group>
        <group group_id="B2">
          <title>Benralizumab 100 mg</title>
          <description>Every 8 weeks administered subcutaneously</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Every 8 weeks administered subcutaneously</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="554"/>
            <count group_id="B2" value="552"/>
            <count group_id="B3" value="550"/>
            <count group_id="B4" value="1656"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Full analysis set</population>
          <units>Year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.9" spread="7.77"/>
                    <measurement group_id="B2" value="65.3" spread="8.05"/>
                    <measurement group_id="B3" value="65.2" spread="8.22"/>
                    <measurement group_id="B4" value="65.5" spread="8.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Full analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="172"/>
                    <measurement group_id="B2" value="180"/>
                    <measurement group_id="B3" value="175"/>
                    <measurement group_id="B4" value="527"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="382"/>
                    <measurement group_id="B2" value="372"/>
                    <measurement group_id="B3" value="375"/>
                    <measurement group_id="B4" value="1129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <population>Full analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="496"/>
                    <measurement group_id="B2" value="493"/>
                    <measurement group_id="B3" value="488"/>
                    <measurement group_id="B4" value="1477"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="140"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS&gt;=220/uL</title>
        <description>A COPD exacerbation is defined by symptomatic worsening of COPD requiring:
Use of systemic corticosteroids for at least 3 days; a single depot injectable dose of corticosteroids will be considered equivalent to a 3-day course of systemic corticosteroids; and/or
Use of antibiotics; and/or
An inpatient hospitalization or death due to COPD Annual COPD exacerbation rate is the number of exacerbations per year. Its raw rate is calculated by number of exacerbations divided by the treatment period and then normalized to an annual rate, and is estimated by negative binomial model. Rate ratio between two treatment groups is also estimated through this model.</description>
        <time_frame>From first IP to week 56</time_frame>
        <population>Full analysis set with baseline EOS&gt;=220/uL</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 100 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS&gt;=220/uL</title>
          <description>A COPD exacerbation is defined by symptomatic worsening of COPD requiring:
Use of systemic corticosteroids for at least 3 days; a single depot injectable dose of corticosteroids will be considered equivalent to a 3-day course of systemic corticosteroids; and/or
Use of antibiotics; and/or
An inpatient hospitalization or death due to COPD Annual COPD exacerbation rate is the number of exacerbations per year. Its raw rate is calculated by number of exacerbations divided by the treatment period and then normalized to an annual rate, and is estimated by negative binomial model. Rate ratio between two treatment groups is also estimated through this model.</description>
          <population>Full analysis set with baseline EOS&gt;=220/uL</population>
          <units>Exacerbations per year</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="382"/>
                <count group_id="O2" value="379"/>
                <count group_id="O3" value="359"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.19" lower_limit="1.04" upper_limit="1.36"/>
                    <measurement group_id="O2" value="1.03" lower_limit="0.9" upper_limit="1.19"/>
                    <measurement group_id="O3" value="1.24" lower_limit="1.08" upper_limit="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6490</p_value>
            <method>Negative binomial</method>
            <method_desc>Model includes treatment group, EOS cohort, region, background therapy, number of exacerbations in the previous year.</method_desc>
            <param_type>Rate ratio</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0525</p_value>
            <method>Negative binomial</method>
            <method_desc>Model includes treatment group, EOS cohort, region, background therapy, number of exacerbations in the previous year.</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS&lt;220/uL</title>
        <description>A COPD exacerbation is defined by symptomatic worsening of COPD requiring:
Use of systemic corticosteroids for at least 3 days; a single depot injectable dose of corticosteroids will be considered equivalent to a 3-day course of systemic corticosteroids; and/or
Use of antibiotics; and/or
An inpatient hospitalization or death due to COPD Annual COPD exacerbation rate is the number of exacerbations per year. Its raw rate is calculated by number of exacerbations divided by the treatment period and then normalized to an annual rate, and is estimated by negative binomial model. Rate ratio between two treatment groups is also estimated through this model.</description>
        <time_frame>From first IP to week 56</time_frame>
        <population>Full analysis set with baseline EOS&lt;220/uL</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 100 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS&lt;220/uL</title>
          <description>A COPD exacerbation is defined by symptomatic worsening of COPD requiring:
Use of systemic corticosteroids for at least 3 days; a single depot injectable dose of corticosteroids will be considered equivalent to a 3-day course of systemic corticosteroids; and/or
Use of antibiotics; and/or
An inpatient hospitalization or death due to COPD Annual COPD exacerbation rate is the number of exacerbations per year. Its raw rate is calculated by number of exacerbations divided by the treatment period and then normalized to an annual rate, and is estimated by negative binomial model. Rate ratio between two treatment groups is also estimated through this model.</description>
          <population>Full analysis set with baseline EOS&lt;220/uL</population>
          <units>Exacerbations per year</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="173"/>
                <count group_id="O3" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="1.19" upper_limit="1.64"/>
                    <measurement group_id="O2" value="1.32" lower_limit="1.12" upper_limit="1.56"/>
                    <measurement group_id="O3" value="1.30" lower_limit="1.11" upper_limit="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5236</p_value>
            <method>Negative binomial</method>
            <method_desc>Model includes treatment group, region, number of exacerbations in the previous year.</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8812</p_value>
            <method>Negative binomial</method>
            <method_desc>Model includes treatment group, EOS cohort, region, number of exacerbations in the previous year.</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline EOS&gt;=220/uL</title>
        <description>Pre-bronchodilator FEV1 (L) is collected at Weeks 0, 4, 8, 16, 24, 32, 40, 48, and 56. Baseline is the last non-missing value with quality (acceptable or borderline quality grade) prior to the first dose of study treatment.</description>
        <time_frame>First IP up to end of treatment Week 56</time_frame>
        <population>Full analysis set, baseline EOS&gt;=220/uL</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 100 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline EOS&gt;=220/uL</title>
          <description>Pre-bronchodilator FEV1 (L) is collected at Weeks 0, 4, 8, 16, 24, 32, 40, 48, and 56. Baseline is the last non-missing value with quality (acceptable or borderline quality grade) prior to the first dose of study treatment.</description>
          <population>Full analysis set, baseline EOS&gt;=220/uL</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="329"/>
                <count group_id="O2" value="326"/>
                <count group_id="O3" value="317"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.014" spread="0.282"/>
                    <measurement group_id="O2" value="0.031" spread="0.294"/>
                    <measurement group_id="O3" value="0.010" spread="0.275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7550</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment group, baseline FEV1 value, EOS cohort, region, background therapy, visit, and treatment by visit interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.007</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.035</ci_lower_limit>
            <ci_upper_limit>0.048</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3285</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment group, baseline FEV1 value, EOS cohort, region, background therapy, visit, and treatment by visit interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.021</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.021</ci_lower_limit>
            <ci_upper_limit>0.062</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in SGRQ Total Score for Patients With Baseline EOS&gt;=220/uL</title>
        <description>SGRQ is from 50-item PRO instrument. The SGRQ total score is expressed as a percentage of overall impairment, in which 100% means the worst possible health status and 0 indicates the best possible health status.</description>
        <time_frame>First IP up to Week 56</time_frame>
        <population>Full analysis set, baseline EOS&gt;=220/uL</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 100 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in SGRQ Total Score for Patients With Baseline EOS&gt;=220/uL</title>
          <description>SGRQ is from 50-item PRO instrument. The SGRQ total score is expressed as a percentage of overall impairment, in which 100% means the worst possible health status and 0 indicates the best possible health status.</description>
          <population>Full analysis set, baseline EOS&gt;=220/uL</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="338"/>
                <count group_id="O2" value="331"/>
                <count group_id="O3" value="317"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.025" spread="14.677"/>
                    <measurement group_id="O2" value="-6.723" spread="15.723"/>
                    <measurement group_id="O3" value="-3.913" spread="15.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2906</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment group, baseline SGRQ score, EOS cohort, region, background therapy, visit, and treatment by visit interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.011</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.887</ci_lower_limit>
            <ci_upper_limit>0.865</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0264</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment group, baseline SGRQ score, EOS cohort, region, background therapy, visit, and treatment by visit interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.136</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.020</ci_lower_limit>
            <ci_upper_limit>-0.251</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in CAT Total Score for Patients With Baseline EOS&gt;=220/uL</title>
        <description>CAT is an 8-item PRO developed to measure the impact of COPD on health status. The instrument uses semantic differential six-point response scales. A CAT total score is the sum of item responses. Score ranges from 0 to 40 with higher scores indicative of greater COPD impact on health status.</description>
        <time_frame>First IP up to Week 56</time_frame>
        <population>Full analysis set, baseline EOS&gt;=220/uL</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 100 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in CAT Total Score for Patients With Baseline EOS&gt;=220/uL</title>
          <description>CAT is an 8-item PRO developed to measure the impact of COPD on health status. The instrument uses semantic differential six-point response scales. A CAT total score is the sum of item responses. Score ranges from 0 to 40 with higher scores indicative of greater COPD impact on health status.</description>
          <population>Full analysis set, baseline EOS&gt;=220/uL</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="338"/>
                <count group_id="O2" value="335"/>
                <count group_id="O3" value="319"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.50" spread="6.89"/>
                    <measurement group_id="O2" value="-2.43" spread="6.34"/>
                    <measurement group_id="O3" value="-1.22" spread="6.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6782</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment group, baseline CAT total score, EOS cohort, region, background therapy, visit, and treatment by visit interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.08</ci_lower_limit>
            <ci_upper_limit>0.70</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0753</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment group, baseline CAT total score, EOS cohort, region, background therapy, visit, and treatment by visit interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.70</ci_lower_limit>
            <ci_upper_limit>0.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in E-RS: COPD Total Score for Patients With Baseline EOS&gt;=220/uL</title>
        <description>The E-RS: COPD is an 11-item PRO developed to evaluate the severity of respiratory symptoms of COPD. Summation of E-RS: COPD item responses produces a total score ranging from 0 to 40, with higher scores indicating greater severity.</description>
        <time_frame>First IP up to Week 56</time_frame>
        <population>Full analysis set, baseline EOS&gt;=220/uL</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 100 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in E-RS: COPD Total Score for Patients With Baseline EOS&gt;=220/uL</title>
          <description>The E-RS: COPD is an 11-item PRO developed to evaluate the severity of respiratory symptoms of COPD. Summation of E-RS: COPD item responses produces a total score ranging from 0 to 40, with higher scores indicating greater severity.</description>
          <population>Full analysis set, baseline EOS&gt;=220/uL</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="324"/>
                <count group_id="O2" value="328"/>
                <count group_id="O3" value="295"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.085" spread="5.273"/>
                    <measurement group_id="O2" value="-1.354" spread="5.599"/>
                    <measurement group_id="O3" value="-0.504" spread="5.674"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0889</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment group, baseline total score, EOS cohort, region, background therapy, visit, and treatment by visit interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.585</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.260</ci_lower_limit>
            <ci_upper_limit>0.089</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0413</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment group, baseline total score, EOS cohort, region, background therapy, visit, and treatment by visit interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.703</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.378</ci_lower_limit>
            <ci_upper_limit>-0.028</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Total Rescue Medication Use (Number of Puffs Per Day) for Patients With Baseline EOS&gt;=220/uL</title>
        <description>The number of rescue medication inhalations and nebulizer treatments taken are recorded by the patient in the eDiary twice daily. Total rescue medication use is the sum of daytime and night-time use.</description>
        <time_frame>First IP up to Week 56</time_frame>
        <population>Full analysis set, baseline EOS&gt;=220/uL</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 100 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Total Rescue Medication Use (Number of Puffs Per Day) for Patients With Baseline EOS&gt;=220/uL</title>
          <description>The number of rescue medication inhalations and nebulizer treatments taken are recorded by the patient in the eDiary twice daily. Total rescue medication use is the sum of daytime and night-time use.</description>
          <population>Full analysis set, baseline EOS&gt;=220/uL</population>
          <units>Puffs/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="321"/>
                <count group_id="O2" value="322"/>
                <count group_id="O3" value="291"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="3.21"/>
                    <measurement group_id="O2" value="-0.27" spread="2.71"/>
                    <measurement group_id="O3" value="0.29" spread="3.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0728</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment group, baseline rescue med. use, EOS cohort, region, background therapy, visit, and treatment by visit interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.348</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.728</ci_lower_limit>
            <ci_upper_limit>0.032</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0121</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment group, baseline rescue med. use, EOS cohort, region, background therapy, visit, and treatment by visit interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.487</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.868</ci_lower_limit>
            <ci_upper_limit>-0.107</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Proportion of Nights Awakenings Due to Respiratory Symptoms for Patients With Baseline EOS&gt;=220/uL</title>
        <description>Change from baseline to week 56 in proportion of nights awakenings due to respiratory symptoms.</description>
        <time_frame>First IP up to Week 56</time_frame>
        <population>Full analysis set, baseline EOS&gt;=220/uL</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 100 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Proportion of Nights Awakenings Due to Respiratory Symptoms for Patients With Baseline EOS&gt;=220/uL</title>
          <description>Change from baseline to week 56 in proportion of nights awakenings due to respiratory symptoms.</description>
          <population>Full analysis set, baseline EOS&gt;=220/uL</population>
          <units>Proportion of nights</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="325"/>
                <count group_id="O2" value="323"/>
                <count group_id="O3" value="297"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.088" spread="0.310"/>
                    <measurement group_id="O2" value="-0085" spread="0.283"/>
                    <measurement group_id="O3" value="-0.049" spread="0.307"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0235</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment group, baseline prop. of nights awakens., EOS cohort, region, background therapy, visit, and treatment by visit interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.041</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.077</ci_lower_limit>
            <ci_upper_limit>-0.006</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0158</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment group, baseline prop. of nights awakens., EOS cohort, region, background therapy, visit, and treatment by visit interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.044</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.080</ci_lower_limit>
            <ci_upper_limit>-0.008</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants by Number of COPD Exacerbations Based on EXACT-PRO for Patients With Baseline EOS&gt;=220/uL</title>
        <description>The EXACT-PRO is a 14-item PRO instrument developed to assess the frequency, severity and duration of COPD exacerbations. Respondents are instructed to complete the electronic diary (eDiary) each evening just prior to bedtime and to answer the questions while onsidering their experiences &quot;today&quot;. The daily EXACT-PRO total score has a range of 0-100 with higher scores indicative of greater severity. Exacerbation event frequency is calculated by comparing the baseline with daily total scores. An increase in EXACT-PRO total score ≥9 for 3 days or ≥12 for 2 days indicate an exacerbation event has occurred.</description>
        <time_frame>Immediately following first IP up to week 56</time_frame>
        <population>Full analysis set, EOS&gt;=220/uL</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 100 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants by Number of COPD Exacerbations Based on EXACT-PRO for Patients With Baseline EOS&gt;=220/uL</title>
          <description>The EXACT-PRO is a 14-item PRO instrument developed to assess the frequency, severity and duration of COPD exacerbations. Respondents are instructed to complete the electronic diary (eDiary) each evening just prior to bedtime and to answer the questions while onsidering their experiences &quot;today&quot;. The daily EXACT-PRO total score has a range of 0-100 with higher scores indicative of greater severity. Exacerbation event frequency is calculated by comparing the baseline with daily total scores. An increase in EXACT-PRO total score ≥9 for 3 days or ≥12 for 2 days indicate an exacerbation event has occurred.</description>
          <population>Full analysis set, EOS&gt;=220/uL</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="382"/>
                <count group_id="O2" value="378"/>
                <count group_id="O3" value="358"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0</title>
                  <measurement_list>
                    <measurement group_id="O1" value="180"/>
                    <measurement group_id="O2" value="184"/>
                    <measurement group_id="O3" value="179"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1</title>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="103"/>
                    <measurement group_id="O3" value="99"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2</title>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>6</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>7</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>8</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>9</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>10</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of EXACT-PRO for Patients With Baseline EOS&gt;=220/uL</title>
        <description>The EXACT-PRO is a 14-item PRO instrument developed to assess the frequency, severity and duration of COPD exacerbations. Respondents are instructed to complete the electronic diary (eDiary) each evening just prior to bedtime and to answer the questions while onsidering their experiences &quot;today&quot;. The daily EXACT-PRO total score has a range of 0-100 with higher scores indicative of greater severity. Severity for the study is the highest score of EXACT-PRO.</description>
        <time_frame>Immediately following first IP up to week 56</time_frame>
        <population>Full analysis set, baseline EOS&gt;=220/uL</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 100 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of EXACT-PRO for Patients With Baseline EOS&gt;=220/uL</title>
          <description>The EXACT-PRO is a 14-item PRO instrument developed to assess the frequency, severity and duration of COPD exacerbations. Respondents are instructed to complete the electronic diary (eDiary) each evening just prior to bedtime and to answer the questions while onsidering their experiences &quot;today&quot;. The daily EXACT-PRO total score has a range of 0-100 with higher scores indicative of greater severity. Severity for the study is the highest score of EXACT-PRO.</description>
          <population>Full analysis set, baseline EOS&gt;=220/uL</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="194"/>
                <count group_id="O3" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.5" spread="11.30"/>
                    <measurement group_id="O2" value="50.8" spread="10.70"/>
                    <measurement group_id="O3" value="52.0" spread="11.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of EXACT-PRO for Patients With Baseline EOS&gt;=220/uL</title>
        <description>The EXACT-PRO is a 14-item PRO instrument developed to assess the frequency, severity and duration of COPD exacerbations. Respondents are instructed to complete the electronic diary (eDiary) each evening just prior to bedtime and to answer the questions while onsidering their experiences &quot;today&quot;. The daily EXACT-PRO total score has a range of 0-100 with higher scores indicative of greater severity. Event frequency is calculated by comparing the baseline with daily total scores. An increase in EXACT-PRO total score ≥9 for 3 days or ≥12 for 2 days indicate an event has occurred. Calculation of event duration after identification of the following five parameters: 1) onset; 2) three-day rolling average; 3) maximum observed value; 4) threshold for improvement; and 5) recovery. That is, duration of the exacerbation is the time elapse between onset and recovery of the event.</description>
        <time_frame>Immediately following first IP up to week 56</time_frame>
        <population>Full analysis set, baseline EOS&gt;=220/uL</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 100 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of EXACT-PRO for Patients With Baseline EOS&gt;=220/uL</title>
          <description>The EXACT-PRO is a 14-item PRO instrument developed to assess the frequency, severity and duration of COPD exacerbations. Respondents are instructed to complete the electronic diary (eDiary) each evening just prior to bedtime and to answer the questions while onsidering their experiences &quot;today&quot;. The daily EXACT-PRO total score has a range of 0-100 with higher scores indicative of greater severity. Event frequency is calculated by comparing the baseline with daily total scores. An increase in EXACT-PRO total score ≥9 for 3 days or ≥12 for 2 days indicate an event has occurred. Calculation of event duration after identification of the following five parameters: 1) onset; 2) three-day rolling average; 3) maximum observed value; 4) threshold for improvement; and 5) recovery. That is, duration of the exacerbation is the time elapse between onset and recovery of the event.</description>
          <population>Full analysis set, baseline EOS&gt;=220/uL</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="194"/>
                <count group_id="O3" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.2" spread="95.80"/>
                    <measurement group_id="O2" value="88.3" spread="105.30"/>
                    <measurement group_id="O3" value="101.7" spread="113.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annual EXACT-PRO Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS&gt;=220/uL</title>
        <description>The EXACT-PRO is a 14-item PRO instrument developed to assess the frequency, severity and duration of COPD exacerbations. Respondents are instructed to complete the electronic diary (eDiary) each evening just prior to bedtime and to answer the questions while onsidering their experiences &quot;today&quot;. The daily EXACT-PRO total score has a range of 0-100 with higher scores indicative of greater severity. Event frequency is calculated by comparing the baseline with daily total scores. An increase in EXACT-PRO total score ≥9 for 3 days or ≥12 for 2 days indicate an event has occurred. Annual EXACT-PRO exacerbation rate is the number of exacerbations per year. Its raw rate is calculated by number of exacerbations divided by the treatment period and then normalized to an annual rate, and is estimated by negative binomial model. Rate ratio between two treatment groups is also estimated through this model.</description>
        <time_frame>Immediately following first IP up to week 56</time_frame>
        <population>Full analysis set, baseline EOS&gt;=220/uL</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 100 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Annual EXACT-PRO Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS&gt;=220/uL</title>
          <description>The EXACT-PRO is a 14-item PRO instrument developed to assess the frequency, severity and duration of COPD exacerbations. Respondents are instructed to complete the electronic diary (eDiary) each evening just prior to bedtime and to answer the questions while onsidering their experiences &quot;today&quot;. The daily EXACT-PRO total score has a range of 0-100 with higher scores indicative of greater severity. Event frequency is calculated by comparing the baseline with daily total scores. An increase in EXACT-PRO total score ≥9 for 3 days or ≥12 for 2 days indicate an event has occurred. Annual EXACT-PRO exacerbation rate is the number of exacerbations per year. Its raw rate is calculated by number of exacerbations divided by the treatment period and then normalized to an annual rate, and is estimated by negative binomial model. Rate ratio between two treatment groups is also estimated through this model.</description>
          <population>Full analysis set, baseline EOS&gt;=220/uL</population>
          <units>Exacerbations per year</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="382"/>
                <count group_id="O2" value="378"/>
                <count group_id="O3" value="358"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.14" lower_limit="0.98" upper_limit="1.31"/>
                    <measurement group_id="O2" value="1.02" lower_limit="0.88" upper_limit="1.19"/>
                    <measurement group_id="O3" value="1.04" lower_limit="0.90" upper_limit="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4080</p_value>
            <method>Negative binomial</method>
            <method_desc>Model includes treatment group, EOS cohort, region, background therapy, number of exacerbations in the previous year.</method_desc>
            <param_type>Rate ratio</param_type>
            <param_value>1.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8688</p_value>
            <method>Negative binomial</method>
            <method_desc>Model includes treatment group, EOS cohort, region, background therapy, number of exacerbations in the previous year.</method_desc>
            <param_type>Rate ratio</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Having at Least 1 COPD Exacerbation for Patients With Baseline EOS&gt;=220/uL</title>
        <description>A COPD exacerbation is defined by symptomatic worsening COPD requiring systemic corticosteroids, antibiotics, or an inpatient hospitalization/death due to COPD.</description>
        <time_frame>Immediately following first IP up to week 56</time_frame>
        <population>Full analysis set, baseline EOS&gt;=220/uL</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 100 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Having at Least 1 COPD Exacerbation for Patients With Baseline EOS&gt;=220/uL</title>
          <description>A COPD exacerbation is defined by symptomatic worsening COPD requiring systemic corticosteroids, antibiotics, or an inpatient hospitalization/death due to COPD.</description>
          <population>Full analysis set, baseline EOS&gt;=220/uL</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="382"/>
                <count group_id="O2" value="379"/>
                <count group_id="O3" value="359"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="204"/>
                    <measurement group_id="O2" value="203"/>
                    <measurement group_id="O3" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Proportion of participants with &gt;=1 COPD exacerbation.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4850</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test controlling for EOS cohort, region, and background therapy.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Proportion of participants with &gt;=1 COPD exacerbation.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4489</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test controlling for EOS cohort, region, and background therapy.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First COPD Exacerbation</title>
        <description>Time to first COPD exacerbation is from the randomization date to the first occurrence of COPD exacerbation</description>
        <time_frame>Immediately following first IP up to week 56</time_frame>
        <population>Full analysis set, baseline EOS&gt;=220/uL</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 100 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First COPD Exacerbation</title>
          <description>Time to first COPD exacerbation is from the randomization date to the first occurrence of COPD exacerbation</description>
          <population>Full analysis set, baseline EOS&gt;=220/uL</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="382"/>
                <count group_id="O2" value="379"/>
                <count group_id="O3" value="359"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="333" lower_limit="273" upper_limit="400"/>
                    <measurement group_id="O2" value="329" lower_limit="262" upper_limit="396"/>
                    <measurement group_id="O3" value="337" lower_limit="261" upper_limit="390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annual COPD Exacerbation Rate Associated With ER or Hospitalization Over 56 Weeks Treatment Comparison for Patients With Baseline EOS&gt;=220/uL</title>
        <description>Annual COPD exacerbations rate that result in ER or hospitalization is calculated by number of exacerbations resulting ER or hospitalization divided by the treatment period and then normalized to an annual rate, and is estimated by negative binomial model. Rate ratio between two treatment groups is also estimated through this model.</description>
        <time_frame>Immediately following first IP up to week 56</time_frame>
        <population>Full analysis set, baseline EOS&gt;=220/uL</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 100 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Annual COPD Exacerbation Rate Associated With ER or Hospitalization Over 56 Weeks Treatment Comparison for Patients With Baseline EOS&gt;=220/uL</title>
          <description>Annual COPD exacerbations rate that result in ER or hospitalization is calculated by number of exacerbations resulting ER or hospitalization divided by the treatment period and then normalized to an annual rate, and is estimated by negative binomial model. Rate ratio between two treatment groups is also estimated through this model.</description>
          <population>Full analysis set, baseline EOS&gt;=220/uL</population>
          <units>Exacerbations per year</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="382"/>
                <count group_id="O2" value="379"/>
                <count group_id="O3" value="359"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" lower_limit="0.20" upper_limit="0.35"/>
                    <measurement group_id="O2" value="0.15" lower_limit="0.11" upper_limit="0.20"/>
                    <measurement group_id="O3" value="0.25" lower_limit="0.19" upper_limit="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7733</p_value>
            <method>Negative binomial</method>
            <method_desc>Model includes treatment group, EOS cohort, region, background therapy, previous year exacerbations associated with hospitalization (Y/N).</method_desc>
            <param_type>Rate ratio</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>1.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0114</p_value>
            <method>Nagative binomial</method>
            <method_desc>Model includes treatment group, EOS cohort, region, background therapy, previous year exacerbations associated with hospitalization (Y/N).</method_desc>
            <param_type>Rate ratio</param_type>
            <param_value>0.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.39</ci_lower_limit>
            <ci_upper_limit>0.89</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Had COPD-related Healthcare Encounter for Patient With Baseline EOS&gt;=220/uL</title>
        <description>Types of healthcare encounter: Hospitalisations (inc. intensive care and/or general care), Emergency department visits, Unscheduled outpatients visits, Home visits, Telephone calls, and ambulance transports.</description>
        <time_frame>Immediately following first IP up to week 56</time_frame>
        <population>Full analysis set, baseline EOS&gt;=220/uL</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 100 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Had COPD-related Healthcare Encounter for Patient With Baseline EOS&gt;=220/uL</title>
          <description>Types of healthcare encounter: Hospitalisations (inc. intensive care and/or general care), Emergency department visits, Unscheduled outpatients visits, Home visits, Telephone calls, and ambulance transports.</description>
          <population>Full analysis set, baseline EOS&gt;=220/uL</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="382"/>
                <count group_id="O2" value="379"/>
                <count group_id="O3" value="359"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hospitalisations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emergency Department Visits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unscheduled Outpatient Visits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219"/>
                    <measurement group_id="O2" value="236"/>
                    <measurement group_id="O3" value="202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Home Visits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Telephone calls</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="111"/>
                    <measurement group_id="O3" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ambulance transports</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Study Treatment Administration</title>
        <description>Duration of study treatment is calculated from first dose date to last dose date + 1 day.</description>
        <time_frame>From first dose date to last dose date, 48 weeks per protocol.</time_frame>
        <population>Safety analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 100 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Study Treatment Administration</title>
          <description>Duration of study treatment is calculated from first dose date to last dose date + 1 day.</description>
          <population>Safety analysis set</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="554"/>
                <count group_id="O2" value="552"/>
                <count group_id="O3" value="550"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="302.4" spread="85.73"/>
                    <measurement group_id="O2" value="304.0" spread="82.40"/>
                    <measurement group_id="O3" value="302.5" spread="88.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Concentration of Benralizumab</title>
        <description>PK serum samples were collected pre-dose at each visit.</description>
        <time_frame>Pre-first dose and pre-dose at end of treatment (week 56)</time_frame>
        <population>PK analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 100 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Concentration of Benralizumab</title>
          <description>PK serum samples were collected pre-dose at each visit.</description>
          <population>PK analysis set</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="553"/>
                <count group_id="O2" value="550"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="548"/>
                    <count group_id="O2" value="544"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">&lt;LLOQ (Lower limit of quantification)</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">&lt;LLOQ (Lower limit of quantification)</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="375"/>
                    <count group_id="O2" value="391"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219.45" spread="233.21"/>
                    <measurement group_id="O2" value="699.89" spread="243.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity of Benralizumab</title>
        <description>Antidrug antibody (ADA) responses such as ADA prevalence, ADA incidence, ADA persistently positive counts, etc. were presented</description>
        <time_frame>Pre-treatment until end of follow-up, week 60 per protocol.</time_frame>
        <population>safety analysis set. For each parameter, the number of subjects at risk is to be analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab 30 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Benralizumab 100 mg</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Every 8 weeks administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity of Benralizumab</title>
          <description>Antidrug antibody (ADA) responses such as ADA prevalence, ADA incidence, ADA persistently positive counts, etc. were presented</description>
          <population>safety analysis set. For each parameter, the number of subjects at risk is to be analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="554"/>
                <count group_id="O2" value="552"/>
                <count group_id="O3" value="550"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ADA prevalence</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="554"/>
                    <count group_id="O2" value="552"/>
                    <count group_id="O3" value="550"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADA incidence</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="547"/>
                    <count group_id="O2" value="542"/>
                    <count group_id="O3" value="535"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Both base/post-baseline positive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="547"/>
                    <count group_id="O2" value="542"/>
                    <count group_id="O3" value="535"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Only post baseline positive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="551"/>
                    <count group_id="O2" value="547"/>
                    <count group_id="O3" value="537"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Only baseline positive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="550"/>
                    <count group_id="O2" value="547"/>
                    <count group_id="O3" value="548"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADA persistently positive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="547"/>
                    <count group_id="O2" value="542"/>
                    <count group_id="O3" value="535"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADA transiently positive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="547"/>
                    <count group_id="O2" value="542"/>
                    <count group_id="O3" value="535"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>nAb prevalence</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="554"/>
                    <count group_id="O2" value="552"/>
                    <count group_id="O3" value="550"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>nAb incidence</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="547"/>
                    <count group_id="O2" value="542"/>
                    <count group_id="O3" value="535"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the time the patient signed informed consent through the treatment period up to the follow-up visit (week 60).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Benralizumab 30 mg</title>
          <description>Every 8 weeks administered subcutaneously</description>
        </group>
        <group group_id="E2">
          <title>Benralizumab 100 mg</title>
          <description>Every 8 weeks administered subcutaneously</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Every 8 weeks administered subcutaneously</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="552"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="151" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="177" subjects_at_risk="552"/>
                <counts group_id="E3" subjects_affected="176" subjects_at_risk="550"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Hypochromic anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Acute right ventricular failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="554"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="552"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Aortic valve disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="554"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="552"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="554"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="554"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Cor pulmonale chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Coronary artery insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="554"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Exomphalos</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal wall haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="554"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Gastrointestinal necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Intestinal polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="552"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Mallory-Weiss syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Oesophageal spasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Peritoneal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Salivary gland calculus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Atypical mycobacterial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Atypical mycobacterial lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="552"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary aspergillosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Cellulitis pharyngeal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Disseminated tuberculosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Infectious pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Periorbital cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="24" subjects_affected="22" subjects_at_risk="554"/>
                <counts group_id="E2" events="19" subjects_affected="18" subjects_at_risk="552"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="554"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="552"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Pneumonia haemophilus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Pneumonia klebsiella</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Pneumonia moraxella</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Pneumonia necrotising</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Pneumonia pseudomonal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Pneumonia streptococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Rhinovirus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="554"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Airway burns</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Arterial bypass occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Asbestosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Dural tear</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Fractured coccyx</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Skin flap necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Traumatic haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Vascular bypass dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Vascular graft occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Vascular procedure complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram ST-T change</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Gouty arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma gastric</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Benign lung neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Colon neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Glioblastoma multiforme</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Haemangioma of skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Laryngeal squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer stage IIIB</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Prostate cancer stage II</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Renal neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Sarcoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Tonsil cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Facial paralysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Generalised tonic-clonic seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Hyperaesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Hypoxic-ischaemic encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Monoparesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Radicular syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Stupor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Thrombotic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Anxiety disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="145" subjects_affected="97" subjects_at_risk="554"/>
                <counts group_id="E2" events="101" subjects_affected="78" subjects_at_risk="552"/>
                <counts group_id="E3" events="142" subjects_affected="100" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Chronic respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Hypercapnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Lung consolidation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Pickwickian syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Pneumothorax spontaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatomyositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Erythema nodosum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Skin laxity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="554"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Peripheral venous disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="554"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="550"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="293" subjects_at_risk="554"/>
                <counts group_id="E2" subjects_affected="318" subjects_at_risk="552"/>
                <counts group_id="E3" subjects_affected="282" subjects_at_risk="550"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="554"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="552"/>
                <counts group_id="E3" events="17" subjects_affected="15" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="554"/>
                <counts group_id="E2" events="18" subjects_affected="15" subjects_at_risk="552"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="17" subjects_affected="13" subjects_at_risk="554"/>
                <counts group_id="E2" events="22" subjects_affected="18" subjects_at_risk="552"/>
                <counts group_id="E3" events="15" subjects_affected="13" subjects_at_risk="550"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="554"/>
                <counts group_id="E2" events="28" subjects_affected="26" subjects_at_risk="552"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="550"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="74" subjects_affected="59" subjects_at_risk="554"/>
                <counts group_id="E2" events="113" subjects_affected="84" subjects_at_risk="552"/>
                <counts group_id="E3" events="121" subjects_affected="80" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="76" subjects_affected="50" subjects_at_risk="554"/>
                <counts group_id="E2" events="47" subjects_affected="32" subjects_at_risk="552"/>
                <counts group_id="E3" events="39" subjects_affected="29" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="21" subjects_affected="17" subjects_at_risk="554"/>
                <counts group_id="E2" events="18" subjects_affected="13" subjects_at_risk="552"/>
                <counts group_id="E3" events="16" subjects_affected="15" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="554"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="552"/>
                <counts group_id="E3" events="26" subjects_affected="18" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="21" subjects_affected="15" subjects_at_risk="554"/>
                <counts group_id="E2" events="18" subjects_affected="12" subjects_at_risk="552"/>
                <counts group_id="E3" events="23" subjects_affected="19" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="554"/>
                <counts group_id="E2" events="22" subjects_affected="17" subjects_at_risk="552"/>
                <counts group_id="E3" events="22" subjects_affected="20" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="87" subjects_affected="69" subjects_at_risk="554"/>
                <counts group_id="E2" events="104" subjects_affected="74" subjects_at_risk="552"/>
                <counts group_id="E3" events="97" subjects_affected="65" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="27" subjects_affected="23" subjects_at_risk="554"/>
                <counts group_id="E2" events="30" subjects_affected="22" subjects_at_risk="552"/>
                <counts group_id="E3" events="22" subjects_affected="15" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="126" subjects_affected="83" subjects_at_risk="554"/>
                <counts group_id="E2" events="134" subjects_affected="95" subjects_at_risk="552"/>
                <counts group_id="E3" events="98" subjects_affected="66" subjects_at_risk="550"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="23" subjects_affected="21" subjects_at_risk="554"/>
                <counts group_id="E2" events="30" subjects_affected="25" subjects_at_risk="552"/>
                <counts group_id="E3" events="19" subjects_affected="19" subjects_at_risk="550"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="29" subjects_affected="21" subjects_at_risk="554"/>
                <counts group_id="E2" events="30" subjects_affected="26" subjects_at_risk="552"/>
                <counts group_id="E3" events="21" subjects_affected="20" subjects_at_risk="550"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="554"/>
                <counts group_id="E2" events="20" subjects_affected="14" subjects_at_risk="552"/>
                <counts group_id="E3" events="30" subjects_affected="21" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="30" subjects_affected="24" subjects_at_risk="554"/>
                <counts group_id="E2" events="19" subjects_affected="17" subjects_at_risk="552"/>
                <counts group_id="E3" events="37" subjects_affected="23" subjects_at_risk="550"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="554"/>
                <counts group_id="E2" events="21" subjects_affected="18" subjects_at_risk="552"/>
                <counts group_id="E3" events="17" subjects_affected="13" subjects_at_risk="550"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="554"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="552"/>
                <counts group_id="E3" events="19" subjects_affected="18" subjects_at_risk="550"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>≥ 60 days prior to submission of material for publication/presentation, Institution and PI shall jointly provide AZ with material for review. No publication/presentation may include any of AZ’s Confidential Information without AZ’s written approval. AZ can request Inst. and PI to withhold material from submission for publication/presentation for an additional 90 days to allow AZ to establish and preserve its proprietary rights in the material being submitted for publication or presentation.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ulbaldo Martin</name_or_title>
      <organization>AstraZeneca</organization>
      <phone>1.301.398.0163</phone>
      <email>ulbaldo.martin@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

